A Phase IV Open-label, Multi-centre, Randomised, Dual-arm, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Dolutegravir

Trial Profile

A Phase IV Open-label, Multi-centre, Randomised, Dual-arm, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Dolutegravir

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Jul 2015 Status changed from recruiting to active, no longer recruiting as per United Kingdom Clinical Research Network record.
    • 16 Jun 2015 Accrual to date is 97%, according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top